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O B J E C T I V E S To examine whether individuals with low short-term risk of coronary heart disease
but high lifetime predicted risk of cardiovascular disease (CVD) have greater prevalence of left ventricular
(LV) hypertrophy and increased aortic wall thickness (AWT) than those with low short-term and low
lifetime risk.
B A C KG ROUND Lifetime risk prediction can be used for stratifying individuals younger than 50
years of age into 2 groups: low short-term/high lifetime and low short-term/low lifetime predicted risk
of CVD. Individuals with low short-term/high lifetime risk have a greater burden of subclinical
atherosclerosis as measured by coronary artery calcium and carotid intima-media thickness. However,
75% of individuals with low short-term/high lifetime risk do not have detectable coronary artery
calcium, suggesting the presence of alternative subclinical abnormalities.
METHOD S We stratiﬁed 1,804 Dallas Heart Study subjects between the ages of 30 and 50 years who
had cardiac magnetic resonance into 3 groups: low short-term (10% 10-year risk of coronary heart
disease)/low lifetime predicted risk (39% lifetime risk of CVD), low short-term (10%)/high lifetime risk
(39%), and high short-term risk (10%, prevalent diabetes, or previous stroke, or myocardial
infarction). In those with low short-term risk, we compared measures of LV hypertrophy and AWT
between those with low versus high lifetime risk.
R E S U L T S Subjects with low short-term/high lifetime risk compared with those with low short-term/
low lifetime risk had increased LV mass (men: 95 17 g/m2 vs. 90 12 g/m2 and women: 75 14 g/m2
vs. 71  10 g/m2, respectively; p  0.001 for both). LV concentricity (mass/volume), wall thickness, and
AWT were also signiﬁcantly greater in those with high lifetime risk in this comparison (p  0.001 for all),
but LV end-diastolic volume was not (p  0.3). These associations persisted among participants without
detectable coronary artery calcium.
CONC L U S I O N S Among individuals 30 to 50 years of age with low short-term risk, a high lifetime
predicted risk of CVD is associated with concentric LV hypertrophy and increased AWT. (J Am Coll
Cardiol Img 2010;3:605–13) © 2010 by the American College of Cardiology Foundation
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606isk estimation for coronary heart disease
(CHD) has evolved from a single risk factor
approach to a multivariable approach (i.e., the
Framingham Risk Score) (1,2). This global
isk score aids primary prevention efforts by identi-
ying high-risk patients who may benefit most from
rug therapy in the near term. However, this risk
rediction algorithm has limitations, classifying
ost individuals younger than 50 years of age as
ow risk regardless of risk-factor burden (3–5). In
ontrast, differences in risk-factor burden in
ounger adults can have substantial influence on the
emaining lifetime risk of atherosclerotic complica-
ions, heart failure, and death (4,6–9).
Recently, we showed that among individuals
ounger than 50 years of age with a low 10-year
redicted risk, further stratification into 2 groups of
imilar size is possible: those with low short-term/
igh lifetime predicted risk and those with low
hort-term/low lifetime predicted risk (10). Fur-
thermore, those with low short-term/high
lifetime predicted risk had a greater bur-
den and progression of subclinical athero-
sclerosis as measured by coronary artery
calcium (CAC) and carotid intima-media
thickness (IMT), suggesting that these
structural changes mediate the marked
differences in lifetime risk of atheroscle-
rotic cardiovascular disease (CVD) (11).
Of interest, more than three-fourths of
individuals with low short-term/high life-
time risk were CAC negative (10), sug-
gesting the presence of alternative subclin-
cal abnormalities among those with low short-term
ut high lifetime predicted risk.
Left ventricular hypertrophy (LVH) is an impor-
ant cardiac phenotype that is associated with ad-
erse cardiovascular outcomes including myocardial
nfarction and overall mortality (6,12). In exploring
otential mechanisms for these associations, we
ecently demonstrated that increased left ventricular
LV) mass, wall thickness, and concentricity are
ssociated with subclinical atherosclerosis as mea-
ured by CAC (13). Due to this association with
AC (13), as well as the relationship of LVH with
dverse cardiovascular outcomes (6,12), we hypoth-
sized that adults 30 to 50 years of age with low
hort-term/high lifetime predicted risk of athero-
clerotic CVD would have a greater prevalence of
VH and an increased abdominal aortic wall thick-
ess (AWT), a measure of subclinical aortic ath-
rosclerosis (14), compared with those with low
m
se
e
sshort-term/low lifetime predicted risk. We further cypothesized that these associations would persist
mong CAC-negative individuals.
E T H O D S
he DHS (Dallas Heart Study). The design of the
HS and details of variable definitions were de-
cribed previously (15,16). Briefly, the DHS is a
ultiethnic, population-based study of residents of
allas County that was prospectively designed to
ssess the presence of and risk factors for subclinical
VD. In the present study, we restricted our
nalyses to those who underwent cardiac magnetic
esonance (CMR) and were 30 to 50 years of age at
he time of their third visit in the DHS.
MR. The details of the CMR protocol were pre-
iously described (16). To measure LV cavity and
all volume, the endocardial and epicardial borders
n the slices were traced manually. To address
uality control and potential errors in outliers in the
HS, a second observer rechecked the contours for
02 analyses (10.8% of the short-axis scans). This
ncluded all participants with a raw LV mass 100
(97 individuals), all with a LV mass 2 SDs
bove the mean (105 individuals), and a random
election of an additional 100 individuals from the
emaining participants. The interobserver difference
or LV mass was 9.2  5 g (5.8  3.5%; n  15),
he intraobserver difference was 10.5 8.6 g (7.1
.0%; n  8), and the interscan variability was
.9  10.9 g (2.9  7.5%; n  8) (16), which was
imilar to what we previously reported for the
easurement of LV mass by CMR at our institu-
ion (17). LV concentricity was defined as LV
ass/LV end-diastolic volume. LV mass was in-
exed to 3 commonly used measures of body size
body surface area, height2.7, and fat-free mass), and
VH was defined as LV mass/body surface area
89 g/m2 (women) and 112 g/m2 (men), LV
ass/height2.7 39 g/m2.7 (women) and 48
/m2.7 (men), and LV mass/fat-free mass 3.7
/kg (men and women) (16).
AWT was measured on the infrarenal abdominal
orta (18). Six transverse slices were obtained per
articipant. For each slice, the adventitial and
uminal boundaries were drawn and were converted
o areas, assuming concentric circles, using the
nalytic software. The radius of each was then
alculated, and the mean AWT for each slice was
alculated as the difference between adventitial and
uminal radii. The mean AWT per participant wasB B R E V I A T I O N S
N D A C R O N YM S
WT aortic wall thickness
AC coronary artery calciu
HD coronary heart disea
VD cardiovascular diseas
MT intima-media thickne
V left ventricular
VH left ventricularalculated as the mean value of the corresponding
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607er-slice AWT measures across the number of
lices for each participant. Participants with overt
neurysms were not included in analyses. The
ntraclass correlation coefficient between luminal
ross-sectional area measurements for the 2 observ-
rs was 0.94 and the mean interobserver difference
as 4.2  6.6%, as previously reported (18). We
reviously described the interstudy variability in
WT measurement in our laboratory (0.03  0.15
m; n  32) (19).
lectron beam computed tomography. Electron
eam computed tomography scanning was per-
ormed using an Imatron C-150XP EBCT scanner
Imatron Inc., San Bruno, California) (20). Dupli-
ate scans were performed within 1 to 2 min. CAC
cores were recorded in Agatston units, and the
verage of 2 scans was used as the final CAC score.
s previously described (20), there was high inter-
can variability in CAC scores in the range of 0 to
0. Therefore, CAC was defined as present with a
ean score 10 Agatston units.
isk classiﬁcation deﬁnitions. As suggested by the
dult Treatment Panel III risk assessment tool (1),
e used age, sex, serum levels of total and high-
ensity lipoprotein cholesterol, smoking, blood
ressure, and treatment for hypertension to esti-
ate the short-term risk of CHD. Low predicted
hort-term risk was defined as an estimated 10-year
isk 10% of fatal or nonfatal CHD. Although the
dult Treatment Panel III guidelines define high
hort-term risk as20% (1), we wanted to focus on
ndividuals with truly low short-term risk and
herefore were more inclusive in our definition of
igh short-term risk (10% estimated 10-year risk
r the presence of diabetes mellitus) as in our
revious studies (10). Participants with self-
Table 1. Risk-Factor Stratiﬁcation* and Predicted Lifetime Risk
Low Predicted Lifetime Risk†
All Optimal
Risk Factors
>1 Not Optimal
Risk Factors
Systolic/diastolic BP (mm Hg) 120/80 120–139/80–89
Total cholesterol (mg/dl) 180 180–199
Diabetes‡ — —
Smoking No No
Lifetime risk of CVD (%)§
Men 5.2 (0–12) 36 (23–50)
Women 8.2 (0–22) 27 (18–36)
*Risk factor stratiﬁcation derived from Lloyd-Jones et al. (11). †Predicted lifetim
disease. ‡Diabetes mellitus was included in the original published stratiﬁcation.
factor was not included in the present article. §Data are presented as median
BP  blood pressure; CVD  cardiovascular disease.eported myocardial infarction or stroke were clas-
ified as high short-term risk (n  42). Participants
ith low short-term risk were further divided into 2
ategories: low lifetime predicted risk and high
ifetime predicted risk of atherosclerotic CVD
Table 1) (10,11). All participants with high life-
ime predicted risk had a predicted lifetime risk of
39% through age 95 years and had1 risk factors
equiring medical treatment. This stratification re-
ulted in 3 mutually exclusive risk groups: 1) low
hort-term/low lifetime predicted risk; 2) low
hort-term/high lifetime predicted risk; and 3) high
redicted short-term risk.
tatistical methods. Statistical analyses were per-
ormed using SAS for Windows (release 9.2; SAS
nstitute, Inc., Cary, North Carolina). All analyses
ere stratified by sex. LVH functioned as the
utcome variable, and the risk group functioned as
he predictor variable. Baseline characteristics, mea-
ures of cardiac phenotypes, and prevalent LVH
ere computed for the 3 risk groups. Continuous
ariables were compared using the general linear
odels, whereas categorical variables were com-
ared using the chi-square test or Fisher exact test.
ultiple comparisons were assessed for those vari-
bles that were statistically different across the
roups via Tukey’s method for continuous variables
nd a resampling, bootstrapping technique for cat-
gorical variables. We also created a composite end
oint of subclinical CVD that included the presence
f LVH, detectable CAC, or AWT 75th percen-
ile and compared it across the 3 risk groups. To
ssess whether associations of the risk groups with
VH and AWT were distinct from associations
ith CAC, sensitivity analyses were performed after
xcluding participants with CAC.
ardiovascular Disease in the 5 Strata
High Predicted Lifetime Risk†
1 Elevated
isk Factors
1 Major Risk
Factor
>2 Major Risk
Factors
0–159/90–99 160/100 (or treated) 160/100 (or treated)
200–239 240 (or treated) 240 (or treated)
— — —
No Yes Yes
46 (38–53) 50 (46–55) 69 (62–73)
39 (33–45) 38.8 (35–43) 50.2 (45–56)
k of CVD in participants with low predicted short-term risk of coronary heart
use all diabetic subjects were considered to have high short-term risk, this risk
conﬁdence interval).of C
>
R
14
e ris
Beca
(95%
RA
y
t
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w
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s
h
c
CAC  coronary artery ca
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608E S U L T S
total of 2,707 participants between 30 and 65
ears of age underwent CMR in the DHS. Of
hese, 1,883 participants were 30 to 50 years of age.
nformation on some of the baseline characteristics
racteristics Stratiﬁed by Sex and Risk Group (N  1,804)
Men
Low Short-Term/Low
Lifetime Risk
(n  282)
Low Short-Term/High
Lifetime Risk
(n  405)
High Short-Ter
Risk (n  146
39 6 40 6 43 5*†
39 45 51
37 34 27
18 19 18
122 9 128 14‡ 129 15*
75 7 79 10‡ 80 10*
0 31 38
l) 163 24 187 39‡ 204 48*†
(%) 0 12 24¶
29 5 29 6 30 6
0 46 66†
23 17§ 10*
77 38‡ 25*¶
0 0 42
1 1 3 2‡ 10 7*†
n  SD or percentages. *p  0.001 for comparison of low short-term/low lifetim
t-term risk. ‡p 0.001 for comparison of low short-term/low lifetime risk with low s
igh lifetime risk. p  0.05 and ¶p  0.01 for comparison of low short-term/high
FRS  Framingham 10-year risk; other abbreviation as in Table 1.
f Risk Groups With Cardiac Phenotypes Stratiﬁed by Sex and Ris
Men
Low
Short-Term/Low
Lifetime Risk
(n  282)
Low
Short-Term/High
Lifetime Risk
(n  405)
High Short
Risk (n 
182 32 192 42* 198 4
(g/kg) 2.8 0.3 3.0 0.5* 3.0 0
area (g/m2) 90 12 95 17* 96 1
2.7) 40 7 43 9* 44 1
1.6 0.3 1.7 0.4* 1.8 0
) 12 1.3 12.5 1.6* 12.9 1
rea (ml/m2) 57 10 57 11 55 1
rea (ml/m2) 17 5 18 7 19 1
m) 1.6 0.2 1.7 0.2* 1.8 0
6 17* 31†‡
an  SD or percentages. *p  0.001 for comparison of low short-term/low lifet
with high short-term risk. ‡p  0.001 for comparison of low short-term/high life
rt-term risk. p  0.02 for comparison of low short-term/high lifetime risk with h
lcium; LV  left ventricular; LVEDV  left ventricular end-diastolic volume; LVESV as missing for 79 participants, leaving 1,804 par-
icipants in the present study cohort.
Baseline characteristics of study participants are
hown in Table 2. Almost 86% of the participants
ad low predicted short-term risk. Further stratifi-
ation by predicted lifetime risk resulted in 2
Women
Low Short-Term/Low
Lifetime Risk
(n  426)
Low Short-Term/High
Lifetime Risk
(n  443)
High Short-Term
Risk (n  102)
38 6 41 6‡ 42 6*
43 53§ 56
26 31 22
30 15‡ 23
114 10 125 18‡ 132 19*†
73 7 80 11‡ 82 11*
0 39 60†
160 24 186 39‡ 184 48*
0 11 17
30 8 31 8 37 9*†
0 47 32
15 9§ 14
85 45‡ 54*
0 0 77
0.1 0.1 1 1‡ 2 4*†
k with high short-term risk. †p  0.001 for comparison of low short-term/high
-term/high lifetime risk. §p 0.01 for comparison of low short-term/low lifetime
ime risk with high short-term risk.
roup (N  1,804)
Women
rm
)
Low
Short-Term/Low
Lifetime Risk
(n  426)
Low
Short-Term/High
Lifetime Risk
(n  443)
High Short-Term
Risk (n  102)
132 25 143 32* 164 52†‡
2.8 0.4 3.0 0.5* 3.0 0.7§
71 10 75 14* 79 22†
37 7 39 9* 45 13†‡
1.4 0.2 1.5 0.3* 1.7 0.5†‡
10.2 1.2 10.8 1.5* 11.9 2.2†‡
52 9 51 11 48 9§
13 4 14 7 13 5
1.5 0.2 1.6 0.2* 1.7 0.3†‡
1 8* 19†
risk with low short-term/high lifetime risk. †p  0.001 for comparison of low
risk with high short-term risk. §p  0.01 for comparison of low short-term/low
hort-term risk.Table 2. Baseline Cha
Variable
m
)
Age (yrs)
Race (%)
Black
White
Hispanic
Systolic BP (mm Hg)
Diastolic BP (mm Hg)
Hypertension (%)
Total cholesterol (mg/d
Hypercholesterolemia
BMI (kg/m2)
Smoking (%)
Current
Past
Never
Diabetes (%)
FRS (%)
Data are presented as mea e ris
lifetime risk with high shor hort
risk with low short-term/h lifet
BMI  body mass index;Table 3. Association o k G
Variable
-Te
146
LV mass (g) 4†
LV mass/fat free mass .5†
LV mass/body surface 7†
LV mass/height2.7 (g/m 0†
LV concentricity (g/ml) .4†
LV wall thickness (mm .6†
LVEDV/ body surface a 7
LVESV/ body surface a 5
Aortic wall thickness (m .3†‡
CAC 10 (%)
Data are presented as me ime
short-term/low lifetime risk time
lifetime risk with high sho igh sleft ventricular end-systolic volume.
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609imilarly sized groups with low short-term/low
ifetime predicted risk and low short-term/high
ifetime predicted risk. Although participants with
ow short-term/high lifetime predicted risk had
igher levels of traditional risk factors compared
ith those with low short-term/low lifetime pre-
icted risk (Table 2), the 10-year risk for both
ubgroups (estimated 10-year risk of CHD events
as 3% vs. 1% for men and 1% vs. 0.1% for women,
espectively) was well below the threshold for treat-
ent based on current guidelines (1).
In comparison with participants with low short-
erm/low lifetime predicted risk (Table 3), those
ith low short-term/high lifetime predicted risk
ad greater LV mass, LV wall thickness, concen-
ricity, AWT, and prevalent CAC (p  0.001 for
ll) but similar indexed LV end-diastolic and end-
ystolic volumes.
To assess the prevalence of LVH in the 3 risk
roups, we analyzed indexed LVH as a dichoto-
ous variable. Depending on the method of index-
ng, the age-adjusted odds of LVH were 1.6- to
.3-fold greater in the low short-term/high lifetime
redicted risk group compared with the low short-
erm/low lifetime predicted risk group. The find-
ngs were consistent when LVH was defined by LV
ass in the top tertile for the study cohort (data not
hown). Overall, we observed a similar pattern of
esults across sexes (Fig. 1) and ethnic subgroups
Fig. 2), although not all the associations reached
tatistical significance (likely due to the small sam-
le size of subgroups).
To determine whether our findings were primar-
ly due to any single risk factor, we sequentially
xcluded participants with one of the major risk
actors (i.e., hypertension [n  415], smoking [n 
20], hypercholesterolemia [n  152], and diabetes
ellitus [n  141]). Although exclusion of partic-
pants with hypertension decreased the magnitude
f observed associations, both men and women
respectively) with low short-term/high lifetime risk
ersus those with low short-term/low lifetime risk
ontinued to have higher median values for indexed
V mass (92 g/m2 vs. 88 g/m2 and 72 g/m2 vs. 70
/m2, respectively; p  0.05 for both). Exclusion of
articipants with other major risk factors did not
ignificantly influence our findings (data not
hown).
The composite end point of LVH (irrespective of
ndexing method), CAC, and AWT was 1.3- to
.9-fold more common among participants with
ow short-term/high lifetime predicted risk com- wared with the low short-term/low lifetime pre-
icted risk group (Fig. 3).
ubclinical CVD among CAC-negative partici-
ants. CAC was absent in 80% of the partici-
ants (n  1,525). Of these, 1,363 (89%) had low
redicted short-term risk. In this subgroup, LV
ass, prevalent LVH, and AWT were greater in
articipants with low short-term/high lifetime pre-
icted risk compared with those with low short-
erm/low lifetime predicted risk (Table 4).
I S C U S S I O N
n this large multiethnic population-based study,
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Figure 1. Prevalent LVH Stratiﬁed by the Predicted Risk and Me
Indexing LV Mass
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surface area; FFM  fat-free mass; LV  left ventricular; LVH  left
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610ge were at low predicted short-term risk of CHD.
owever, more than one-half of these participants
ad high lifetime predicted risk for the develop-
ent of atherosclerotic CVD. There was signifi-
antly increased LV mass and 1.6- to 3.3-fold
reater prevalence of LVH (depending on the
ethod of indexing) among participants with low
hort-term/high lifetime predicted risk versus
hose with low short-term/low lifetime predicted
isk. Similarly, there was 1.3- to 1.9-fold increase
n the composite end point of LVH, CAC, and
WT among participants with low short-term/
igh lifetime predicted risk versus those with low
hort-term/low lifetime predicted risk. These
ndings were qualitatively similar across sexes
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V Mass
and whites (B). *p  0.05; †p  0.01; ‡p  0.001. Abbreviations
e 1.nd ethnic groups. In sensitivity analysis, similar dndings were observed after excluding partici-
ants with CAC.
Recently, we found that individuals with low
hort-term but high lifetime predicted risk of ath-
rosclerotic CVD had an increased burden of sub-
linical atherosclerosis as determined by the pres-
nce of CAC, carotid IMT, and CAC progression
ompared with those with low short-term and low
ifetime predicted risk (10). In an analysis of an
ndependent cohort (the DHS), we confirmed that
mong subjects with low short-term risk, those with
igh lifetime predicted risk versus those with low
ifetime predicted risk have an increased burden of
AC. Moreover, we extend this observation to
dditional subclinical CVD phenotypes, including
VH and AWT, the latter being a novel measure of
ubclinical atherosclerosis in a vascular bed distinct
rom the coronary arteries.
VH and high lifetime predicted risk. As seen previ-
usly (10,11), significant differences existed in the
isk-factor burden between individuals with low
hort-term/low lifetime predicted risk and low
hort-term/high lifetime predicted risk. Although
hese risk factors may not lead to evident CVD in
he short-term, they lead to structural changes that
ver a lifetime increase the risk of atherosclerotic
omplications, heart failure, and death (6,8). LVH
as been shown to be associated with subclinical
therosclerosis (13), adverse cardiovascular out-
omes, and overall mortality (6,12). The association
f high lifetime risk with LVH, especially of the
oncentric phenotype, adds validity to using pre-
icted lifetime risk for further risk stratification in
oung adults.
WT and lifetime risk. Atherosclerosis in the periph-
ral arteries is associated with adverse clinical events
21). The risk factors for aortic atherosclerosis are
imilar to those for carotid atherosclerosis and
ncreased aortic IMT demonstrated by ultrasonog-
aphy has been associated with subclinical athero-
clerosis (14,22). However, there are few magnetic
esonance imaging–based data regarding the utility
f AWT as a marker of subclinical atherosclerosis
23), with the majority of studies reporting data on
arotid IMT, aortic plaque burden (24), and plaque
revalence (22). Nevertheless, the association of
igh lifetime risk with increased AWT supports our
revious observations that high lifetime risk is
ssociated with subclinical atherosclerosis (10).
ifetime risk in the absence of CAC. As observed
reviously (10), CAC was absent in 80% of
ndividuals with low short-term/high lifetime pre-  Low
B
  Low
A
Figure 2.
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611ion of high lifetime risk with LVH, concentric
emodeling, and AWT persisted after excluding
articipants with CAC. Specifically, in subjects
ithout detectable CAC, a concentric LVH phe-
otype, prevalent LVH, and an increased AWT
ere more common among participants with low
hort-term/high lifetime predicted risk than those
ith low short-term/low lifetime predicted risk.
hese findings indicate that the association of high
ifetime risk with LV structural changes and ab-
ominal AWT is at least, in part, independent of
oronary atherosclerosis.
linical implications. Lifetime risk prediction is an
merging concept in clinical medicine. In young
dults, the use of short-term risk prediction may be
isleading because many individuals with low
hort-term risk may still be at high risk for the
evelopment of CVD over their remaining life
pan. In these individuals, further risk stratification
sing predicted lifetime risk may assist in better
ommunication of long-term risk and promote
ealthy lifestyle changes. By demonstrating an as-
ociation of high predicted lifetime risk with LVH,
well-established marker of increased adverse
ardiovascular events, and AWT, these data pro-
ide support to the notion that lifetime risk
rediction provides an important and valid refinement
n the classification of young individuals at low short-
erm risk.
tudy strengths and limitations. Our study has sev-
ral strengths. To our knowledge, this is the first
tudy that analyzed the prevalence of LVH and
WT in the context of lifetime predicted risk of
therosclerotic CVD. Also, we included data from a
arge population-based sample with detailed phe-
otyping of participants, including CMR measure-
ents of cardiac structure and function. This al-
owed a more precise determination of the
ssociations between lifetime predicted risk and
VH. Our study also has several limitations. Due to
he cross-sectional design of the study, outcomes
elated to LVH could not be determined. Further-
ore, although the DHS is a multiethnic sample, the
isk prediction algorithm that we applied was derived
rom the Framingham Heart Study, which enrolled
xclusively white subjects. However, published reports
uggest that this risk prediction model provides reli-
ble estimates of CVD burden for both whites and
onwhites (8,25). Although the absolute differences in
V mass and AWT between the 2 groups were small,
hese differences must be interpreted in view of the
act that these individuals are young and apparently
ealthy and the magnitude of these differences would de expected to increase over time. Furthermore, cor-
nary calcification is a later manifestation of coronary
therosclerosis, and the lack of detectable CAC does
ot exclude coronary atherosclerosis.
O N C L U S I O N S
e demonstrated for the first time that participants
ith low short-term/high lifetime predicted risk of
therosclerotic CVD compared with those with low
hort-term/low lifetime predicted risk had a 1.6- to
.3-fold greater prevalence of LVH, significantly
ncreased LV mass of a concentric phenotype, and
ncreased AWT. Further, these associations per-
isted among CAC-negative individuals. These
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Figure 3. Prevalent Subclinical CVD Stratiﬁed by the Predicted
Method of Indexing LV Mass
Men (A) and women (B). To assess prevalent LVH, LV mass was ind
fat-free mass, BSA, and height2.7. Subclinical CVD included the pres
LVH, detectable CAC, or AWT 75th percentile. *p  0.05; †p  0.0
0.001. Other abbreviations as in Figure 1.m risk
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612est that an assessment of lifetime risk of CVD can
id in the identification of a subgroup of individuals
0 to 50 years of age who are at low risk over a
0-year period but nevertheless have a significant
Table 4. Association of Cardiac Structural Parameters and Aorti
Among Coronary Artery Calcium-Negative Participants With Low
Variable
LV mass (g)
LV mass/fat free mass (g/kg)
LV mass/body surface area (g/m2)
LV mass/height2.7 (g/m2.7)
LV concentricity (g/ml)
LV wall thickness (mm)
LVEDV/body surface area (ml/m2)
LVESV/body surface area (ml/m2)
Aortic wall thickness (mm)
Prevalent LVH (indexing LV mass to fat free mass) (%)
Prevalent LVH (indexing LV mass to body surface area) (%)
Prevalent LVH (indexing LV mass to height2.7) (%)
Data are presented as mean  SD or percentages. *p  0.001 for comparison
LVH  left ventricular hypertrophy; other abbreviations as in Table 3.heart disease in the ATP-III risk assess-
ment tool. Prev Med 2008;47:619–23.
Multi-Ethnic Study
Circulation 2009;11eprint requests and correspondence: Dr. Mark H.
razner, University of Texas Southwestern Medical
enter, 5323 Harry Hines Boulevard, Dallas, Texas
all Thickness With Lifetime Risk of Cardiovascular Disease
ort-Term Risk (N  1,363)
Low Short-Term/ Low
Lifetime Risk
(n  663)
Low Short-Term/ High
Lifetime Risk
(n  700)
150 37 163 42*
2.8 0.4 3 0.5*
78 14 84 18*
38 7 40 9*
1.5 0.3 1.6 0.4*
10.9 1.5 11.5 1.7*
54 10 54 10
15 5 15 6
1.56 0.2 1.62 0.2*
2 5*
4 11*
23 31*
w short-term/low lifetime risk with low short-term/high lifetime risk group.subclinical CVD burden. 75390-9047. E-mail: mark.drazner@utsouthwestern.edu.1
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